|
ANGEL2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.80859796425648E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.51230036774075E-10 |
| Normal-vs-Stage2 |
2.59779999733922E-08 |
| Normal-vs-Stage3 |
3.31049999635624E-08 |
| Normal-vs-Stage4 |
1.41580000001529E-06 |
| Stage1-vs-Stage2 |
3.162800E-01 |
| Stage1-vs-Stage3 |
8.033600E-01 |
| Stage1-vs-Stage4 |
8.375400E-01 |
| Stage2-vs-Stage3 |
4.821800E-01 |
| Stage2-vs-Stage4 |
5.432800E-01 |
| Stage3-vs-Stage4 |
9.897800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.90050197801384E-11 |
| Normal-vs-AfricanAmerican |
2.975500E-02 |
| Normal-vs-Asian |
1.205460E-04 |
| Caucasian-vs-AfricanAmerican |
2.122200E-02 |
| Caucasian-vs-Asian |
1.448020E-01 |
| AfricanAmerican-vs-Asian |
3.038600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.16889999796288E-08 |
| Normal-vs-Female |
6.15240081103252E-11 |
| Male-vs-Female |
6.193200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.82729997799669E-09 |
| Normal-vs-Age(41-60Yrs) |
1.63819957599287E-10 |
| Normal-vs-Age(61-80Yrs) |
6.85649999998539E-07 |
| Normal-vs-Age(81-100Yrs) |
1.163550E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.176800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.739000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.929000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.063600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.636600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.195400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.038000E-02 |
| Classical-VS-Follicular |
3.577300E-03 |
| Classical-VS-Other |
5.103200E-01 |
| Classical-VS-Normal |
3.28000000493489E-08 |
| Tall-VS-Follicular |
9.786600E-01 |
| Tall-VS-Other |
7.794000E-01 |
| Tall-VS-Normal |
1.01279999997761E-06 |
| Follicular-VS-Other |
7.665800E-01 |
| Follicular-VS-Normal |
1.03700004139284E-09 |
| Other-VS-Normal |
1.041800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.277300487601E-11 |
| Normal-vs-N1 |
1.72663999999934E-05 |
| N0-vs-N1 |
2.482600E-01 |
|
|
